The global HERG Screening market is projected to reach $4,170.8 million by 2028, expanding at a compound annual growth rate (CAGR) of 13.29% from 2021 to 2028. This growth is driven by various macroeconomic and microeconomic factors, including the rising number of drug approvals, which significantly contribute to the demand for HERG screening.
The latest research report by Evolve Business Intelligence explores the various factors influencing the global market. It includes an analysis of the current market size, forecasts for key segments and regions, and the driving forces behind market growth. The report examines the potential impacts of key trends on business strategies and provides a SWOT analysis of critical sectors for each major competitor and customer group. This valuable data highlights the conglomerates likely to impact the industry, crucial for any company planning to invest strategically over the next five years. These insights complement our initial quantitative study, aiding in new investments and strategic planning to mitigate threats in existing sectors.
Segments covered
By Type (Mutant KCNH2, Gene KCNH2), By Ion Channel (Voltage Gated, Ligand Gated)
By Application (Antiarrhythmic, Antipsychotic, Antibiotics, Others)
Key players
Charles River Laboratories
Eurofins Scientific
Merck KGaA
Cyprotex Limited
BSYS GmbH
Creative bioarray
Metrion biosciences
CREATIVE BIOARRAY
ABCAM PLC.
Aurora Biomed
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook